[{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Incyte"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Specialised Therapeutics \/ Specialised Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Treeway","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Specialised Therapeutics \/ Specialised Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Specialised Therapeutics \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Specialised Therapeutics \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Specialised Therapeutics \/ CanariaBio"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Specialised Therapeutics \/ Ascendis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Ascendis Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Specialised Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Specialised Therapeutics will commercialize Ascendis' injectable pediatric growth hormone SKYTROFA, hypoparathyroidism treatment YORVIPATH, and investigational therapy TransCon CNP.

                          Brand Name : Skytrofa

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 07, 2024

                          Lead Product(s) : Lonapegsomatropin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Ascendis Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.

                          Brand Name : MAb-B43.13

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 12, 2023

                          Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : CanariaBio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the licensing agreement, ST will be responsible for all marketing, regulatory and distribution activities of TW001, a unique oral formulation of edaravone which works by reducing the oxidative damage associated with neuron death in ALS, in Australi...

                          Brand Name : TW001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 28, 2023

                          Lead Product(s) : Edaravone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Treeway

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Monjuvi® and Minjuvi® (tafasitamab) is a humanized Fc-modified CD19 targeting immunotherapy used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

                          Brand Name : Minjuvi

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 28, 2023

                          Lead Product(s) : Tafasitamab,Lenalidomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...

                          Brand Name : Yondelis

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 17, 2023

                          Lead Product(s) : Trabectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 20, 2023

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PEMAZYRE (pemigatinib) a FGFR inhibitor, is used for the treatment of adult patients with metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least one prior line of system...

                          Brand Name : Pemazyre

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 15, 2022

                          Lead Product(s) : Pemigatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Incyte Corporation

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply of both products tafasitamab (sold as Monjuvi) and pemigatinib (Pemazyre) and ST will be responsible for regulatory, distribution and local marketing...

                          Brand Name : Minjuvi

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 22, 2021

                          Lead Product(s) : Tafasitamab,Lenalidomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Incyte Corporation

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : ZEPZELCA® (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers cascade of events that can affect activity of DNA binding proteins, including some transcription factors to treat 2L metastatic small cell lung cancer.

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 22, 2021

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : PharmaMar

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC in Australia in more than 20 years. ZEPZELCA approval granted under a provisional regulatory pathway.

                          Brand Name : Zepzelca

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 14, 2021

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : PharmaMar

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank